A GENE THERAPY FIRST
Ten Bridge was a foundational partner for Spark Therapeutics, building its visual brand and enacting a dynamic communications strategy over several years to support its leadership as the company to deliver the first FDA approved gene therapy for an inherited disease in the United States.
- Media strategy and execution
- Messaging development
- Patient engagement
- Social media/Digital marketing
- Strategic counsel and planning
In the lead-up to a historic FDA Advisory Committee and approval, Ten Bridge designed and executed a comprehensive communications strategy to support the Spark corporate strategy, build understanding and support for its mission, and position the company optimally for approval and commercial launch. This comprehensive engagement involved close partnership across the full spectrum of communications workflows – often without an existing playbook – to help Spark navigate complex issues of defining gene therapy’s value, rare disease patient outreach, and explaining AAV technology to business and lay audiences, among others.
total media circulation
Supported by Ten Bridge, Spark’s story was translated into thousands of pages of media coverage worldwide, and their story of transformational technology for people in need set the stage for a wave of gene therapy technologies that followed.